Navigation Links
Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
Date:10/1/2007

LOS ANGELES, Oct. 1 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN - News) has announced that is has completed in-house testing and technological evaluation of various new modules for its holter and intra- cardiac monitors - items that have previously been an important part of the Company's business plans and are now ready for submission to FDA for clearance. Applications for FDA approval will now be made imminently in the fourth quarter.

Both of these developments are ahead of schedule, and are of importance because they are both revenue producing as well as scientifically significant to the reduction of the $400 billion in cardiovascular expenses as well as to patient health and welfare. Having them completed ahead of schedule will likely bring these products to the forefront several quarters earlier than anticipated - both from a revenue standpoint as well as a scientific venturing standpoint.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
6. PSA TestingHow Much is Too Much?
7. Hemoglobin Testing at the Point of Care
8. Testing for Human Papillomavirus
9. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
10. Rapid HIV Testing Increases Possibility of Treatment
11. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... Oregon and PUNE, India ... to a new report published by Allied Market Research, ... Global Opportunity Analysis and Industry Forecast, 2014-2022," the global ... by 2022, from $5,768 million in 2015, growing at ... chemical & gas sterilization segment dominated the market in ...
(Date:1/16/2017)... , January 16, 2017 According to a new report ... Analysis and Industry Forecast, 2014 - 2022," the global antioxidants market generated $2,923 ... a CAGR of 6.42% during the forecast period. In the natural antioxidants category, ... in 2015. Continue Reading ... ...
(Date:1/16/2017)... 2017   Linde Gas North America LLC  today ... and business of The Service Center LLC, a market leading ... healthcare providers in the Midwest and Southeast regions of the ... , The Service Center also has facilities in ... Carolina . Its primary services include: ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 16, 2017 , ... With the Grand Opening Event planned for February 3, ... sports teams and the general public. Built in five months by Centerpoint, the 60,000 ... into basketball or pickleball courts. The space is also suitable for indoor soccer and ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... manufacturer Prairie Seating. Prairie’s award-winning Reflection® brand of custom seating systems has a ... acquisition provides Permobil with a platform for innovation and growth in the custom ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January 9, 2017 ... Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and ... that strives to better communities around the world by offering the Gensuite team ... the opportunity for team members to become involved in a cause that is ...
Breaking Medicine News(10 mins):